Consequently, data are lacking on the optimal neoadjuvant systemic treatment of patients with HR+/HER2+ breast cancer who are unfit for the combination of chemotherapy and anti-HER2 therapy. This evidence concerns the gene ERBB2 and breast carcinoma.